Skip to content

Ceres Pharma: value indication

Line	Code	2024	2025	Change	%
Total assets	20/58	€214,693,622	€265,887,679	+€51.2m	+23.8%
Formation expenses	20	€3,227,023	€3,148,239	-€78,784	-2.4%
Fixed assets	21/28	€178,328,121	€222,302,369	+€44.0m	+24.7%
Intangible fixed assets	21	€8,986,497	€6,642,591	-€2.3m	-26.1%
Tangible fixed assets	22/27	€644,414	€357,867	-€286,546	-44.5%
Plant, machinery and equipment	23	€261,461	€252,042	-€9,419	-3.6%
Assets under construction and advance payments	27	€382,953	€105,825	-€277,127	-72.4%
Financial fixed assets	28	€168,697,210	€215,301,911	+€46.6m	+27.6%
Affiliated companies	280/1	€168,684,752	€215,292,648	+€46.6m	+27.6%
Participating interests	280	€141,339,752	€170,102,335	+€28.8m	+20.3%
Amounts receivable	281	€27,345,000	€45,190,313	+€17.8m	+65.3%
Other financial fixed assets	284/8	€12,459	€9,263	-€3,196	-25.7%
Amounts receivable and cash guarantees	285/8	€12,459	€9,263	-€3,196	-25.7%
Current assets	29/58	€33,138,478	€40,437,071	+€7.3m	+22.0%
Stocks and contracts in progress	3	€6,793,163	€8,639,921	+€1.8m	+27.2%
Stocks	30/36	€6,793,163	€8,639,921	+€1.8m	+27.2%
Raw materials and consumables	30/31	€60,673	€62,475	+€1,802	+3.0%
Goods purchased for resale	34	€6,732,490	€8,577,446	+€1.8m	+27.4%
Amounts receivable within one year	40/41	€20,223,283	€22,353,088	+€2.1m	+10.5%
Trade receivables	40	€5,946,363	€7,023,597	+€1.1m	+18.1%
Other amounts receivable	41	€14,276,920	€15,329,492	+€1.1m	+7.4%
Current investments	50/53	-	€7,500,000	+€7.5m
Other investments	51/53	-	€7,500,000	+€7.5m
Cash at bank and in hand	54/58	€3,551,221	€395,847	-€3.2m	-88.9%
Deferred charges and accrued income	490/1	€2,570,811	€1,548,215	-€1.0m	-39.8%
Total equity and liabilities	10/49	€214,693,622	€265,887,679	+€51.2m	+23.8%
Equity	10/15	€12,801,257	-€1,550,308	-€14.4m
Contributions	10/11	€50,375,235	€50,375,235	=	0.0%
Capital	10	€50,375,235	€50,375,235	=	0.0%
Issued capital	100	€50,375,235	€50,375,235	=	0.0%
Profit (loss) carried forward	14	-€37,573,977	-€51,925,543	-€14.4m	-38.2%
Amounts payable	17/49	€201,892,365	€267,437,987	+€65.5m	+32.5%
Amounts payable after more than one year	17	€175,330,000	€222,715,000	+€47.4m	+27.0%
Financial debts	170/4	€175,330,000	€222,715,000	+€47.4m	+27.0%
Credit institutions	173	€175,330,000	€222,715,000	+€47.4m	+27.0%
Amounts payable within one year	42/48	€23,480,008	€40,591,460	+€17.1m	+72.9%
Trade debts	44	€13,108,873	€19,051,453	+€5.9m	+45.3%
Suppliers	440/4	€13,108,873	€19,051,453	+€5.9m	+45.3%
Taxes, remuneration and social security	45	€665,858	€684,488	+€18,630	+2.8%
Taxes	450/3	€89,149	€34,743	-€54,406	-61.0%
Remuneration and social security	454/9	€576,709	€649,745	+€73,036	+12.7%
Other amounts payable	47/48	€9,705,277	€20,855,519	+€11.2m	+115%
Accrued charges and deferred income	492/3	€3,082,357	€4,131,528	+€1.0m	+34.0%
Operating income	70/76A	€36,453,686	€38,055,278	+€1.6m	+4.4%
Turnover	70	€35,048,862	€35,316,546	+€267,685	+0.8%
Other operating income	74	€1,361,775	€2,738,732	+€1.4m	+101%
Non-recurring operating income	76A	€43,050	-	-€43,050
Operating charges	60/66A	€35,705,605	€38,068,954	+€2.4m	+6.6%
Goods for resale, raw materials and consumables	60	€16,223,260	€16,477,937	+€254,677	+1.6%
Purchases	600/8	€16,752,463	€18,060,803	+€1.3m	+7.8%
Change in stocks: decrease (increase)	609	-€529,203	-€1,582,866	-€1.1m	-199%
Services and other goods	61	€10,049,919	€10,887,814	+€837,895	+8.3%
Remuneration, social security and pensions	62	€4,467,808	€4,053,765	-€414,044	-9.3%
Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets	630	€3,263,411	€3,061,741	-€201,670	-6.2%
Write-downs on stocks, contracts in progress and trade receivables: additions (reversals)	631/4	€76,807	-€263,107	-€339,914
Other operating charges	640/8	€837,195	€1,294,856	+€457,661	+54.7%
Non-recurring operating charges	66A	€787,205	€2,555,947	+€1.8m	+225%
Operating profit (loss)	9901	€748,081	-€13,676	-€761,757
Financial income	75/76B	€6,068,343	€5,688,314	-€380,029	-6.3%
Recurring financial income	75	€6,068,343	€5,688,314	-€380,029	-6.3%
Income from financial fixed assets	750	€2,814,903	€4,213,260	+€1.4m	+49.7%
Other financial income	752/9	€3,253,440	€1,475,053	-€1.8m	-54.7%
Financial charges	65/66B	€17,270,894	€20,008,215	+€2.7m	+15.8%
Recurring financial charges	65	€17,270,894	€19,355,195	+€2.1m	+12.1%
Debt charges	650	€17,235,411	€19,309,017	+€2.1m	+12.0%
Other financial charges	652/9	€35,483	€46,178	+€10,695	+30.1%
Non-recurring financial charges	66B	-	€653,020	+€653,020
Profit (loss) for the period before taxes	9903	-€10,454,470	-€14,333,577	-€3.9m	-37.1%
Income taxes	67/77	€12,973	€17,988	+€5,015	+38.7%
Taxes	670/3	€12,973	€17,988	+€5,015	+38.7%
Profit (loss) for the period	9904	-€10,467,443	-€14,351,566	-€3.9m	-37.1%
Profit (loss) for the period to be appropriated	9905	-€10,467,443	-€14,351,566	-€3.9m	-37.1%

Ceres Pharma: value indication

Ceres Pharma: value indication

Position among the sector peers

What moved between 2024 and 2025

Largest movements

Change in the result, 2024 to 2025

Derived cash bridge

Value

Indicative value of the equity

Adjusted equity

Capitalised earnings

Your EBITDA multiple

Limits of the indication

Next steps